CJ

C. Jimmy Lin

Cancer Genomics Pioneer and Rare Disease Social Entrepreneur

South San Francisco, California

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Chief Scientific Officer (CSO)

    2019

    Freenome is an AI genomics company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing noninvasive blood tests to detect early-stage cancer and improve precision oncology treatments for patients everywhere. The company has raised more than $500 million from investors such as Andreessen Horowitz, Google Ventures, Polaris Partners, and Founders Fund.​

  • Venture Partner

    2019

    We are a new type of seed-stage fund. We believe business is now truly global. Exceptional entrepreneurs, that are building strong, category defining companies at highly advantageous valuations – can be found anywhere. We are a team highly experienced in finding such talent and helping our entrepreneurs to develop, grow, network, and scale into other markets throughout the world.

  • Founder & Chief Executive Officer (CEO)

    2011

    We help patients with orphan diseases initiate and fund personalized research projects through a dedicated microfunding platform and highly-selective network of leading academic scientists and commercial institutions.

2015 - 2019

  • Chief Scientific Officer (CSO), Oncology

    2015 - 2019

    Natera (NASDAQ: NTRA) is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer - finding circulating DNA (ctDNA) based on liquid biopsy methods.

  • Advisory Panel on Patient Engagement

    2014 - 2018

    PCORI is authorized by Congress to conduct research to provide information about the best-available evidence to help patients and their health care providers make better-informed health and healthcare decisions.

2011 - 2017

  • TED Fellow / Senior Fellow

    2011 - 2017

    TED Fellows program handpicks world-changing innovators from around the globe and brings them to the TED stage -- literally and figuratively -- to raise international awareness of their remarkable work. http://www.ted.com/pages/ted2012_fellows

  • ClinOmics: Intramural Clinical Genomics Program

    2014 - 2015

2013 - 2014

  • Entrepreneur in Residence

    2013 - 2014

    The Mission Center L3C is a think tank for social entrepreneurs, academics, foundations and impact investors who are passionate about finding innovative, business-minded, and sustainable solutions to social problems.

  • Research Instructor

    2011 - 2013

  • Visiting Scientist

    2011 - 2012